Antoni Ribas, MD
Hematology & Oncology · Los Angeles, CANPI 1730109331
Payments from drug & device makers
Across 484 payments — averaging $26,806 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$8.8M
- Pfizer$717K
- Agilent Technologies, Inc.$712K
- GSK$628K
- Dynavax Technologies Corporation$602K
- Tesaro, Inc.$392K
- plus $1.1M from 19 others
Across 18 payments — averaging $1457.89 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$23K
- Regeneron$3K
- F. Hoffmann-la Roche AG$676
- Amgen$6
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 207 | $8,825,452 |
| Pfizer | 24 | $717,031 |
| Agilent Technologies, Inc. | 9 | $712,219 |
| GSK | 90 | $627,553 |
| Dynavax Technologies Corporation | 4 | $602,351 |
| Tesaro, Inc. | 14 | $392,295 |
| Astrazeneca UK Limited | 6 | $343,332 |
| Genentech, Inc. | 16 | $171,615 |
| E.r. Squibb & Sons, L.L.C. | 1 | $168,588 |
| Regeneron | 21 | $102,864 |
| Novartis | 14 | $87,753 |
| Karyopharm Therapeutics Inc. | 9 | $70,742 |
| Hoffmann-la Roche Limited | 6 | $40,568 |
| Amgen | 24 | $39,604 |
| F. Hoffmann-la Roche AG | 9 | $26,104 |
| Sanofi US Services Inc. | 8 | $16,942 |
| Chugai Pharmaceutical Co., Ltd. | 5 | $8,395 |
| AstraZeneca | 1 | $5,000 |
| Jazz Pharmaceuticals Inc. | 2 | $4,544 |
| Immunocore Limited | 6 | $3,510 |
| Gilead | 1 | $3,400 |
| Almirall LLC | 1 | $1,650 |
| Roche Molecular Systems, Inc. | 2 | $1,400 |
| Seagen Inc. | 1 | $1,125 |
| Array Biopharma Inc | 3 | $18 |
How this compares
$12,974,054 in reported general payments places this provider in the 95th percentile of 1,363 hematology & oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Los Angeles
- David BerzLos Angeles$43.3M
- Nicholas McAndrewLos Angeles$22.9M
- Gary SchillerLos Angeles$11.9M
- Matthew RettigLos Angeles$8.2M
- Lasika SeneviratneLos Angeles$8.1M
- Gary BuchschacherLos Angeles$7.9M
- Edward GaronLos Angeles$7.9M
- Gottfried KonecnyLos Angeles$7.6M
- Sven de VosLos Angeles$6.7M
- Jorge NievaLos Angeles$6.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.